Literature DB >> 15948543

External beam radiotherapy in the treatment of male breast carcinoma: patterns of failure in a single institute experience.

Angelika Zabel1, Stefanie Milker-Zabel, Ivan Zuna, Michael Wannenmacher, Jürgen Debus.   

Abstract

AIMS AND
BACKGROUND: We analyzed our own results in the treatment of male breast cancer patients with respect to local control, overall survival and possible prognostic factors for local and distant control.
METHODS: Thirty-one patients with 32 carcinomas of the male breast were treated with radiotherapy. Twenty-five patients received radiotherapy to the chest wall including or not regional lymphatics after initial mastectomy (n = 23) or after surgery for local recurrence (n = 2). Median total dose was 60 Gy to the chest wall and 46 Gy to regional lymphatics. Seven patients with metastatic disease were referred for palliative radiotherapy.
RESULTS: Overall survival after postoperative radiotherapy was 40% after a median follow-up of 4.3 years. Actuarial 3-, 5- and 10-year survival was 82.6%, 56.5% and 43.5%, respectively. Five-year progression-free survival was 62.5%. Survival was significantly affected by the presence of lymph node metastases (P <0.001). Local recurrence was seen in one patient after 29 months.
CONCLUSIONS: Postoperative radiotherapy is important in the management of male breast cancer to improve local control and progression-free survival, resulting in one local failure in our analysis. The presence of lymph node metastases significantly impairs survival.

Entities:  

Mesh:

Year:  2005        PMID: 15948543     DOI: 10.1177/030089160509100209

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Male Breast Cancer.

Authors:  Christian Rudlowski
Journal:  Breast Care (Basel)       Date:  2008-06-24       Impact factor: 2.860

2.  Adjuvant Radiation Therapy for Male Breast Cancer-A Rare Indication?

Authors:  Tobias Forster; Clara Köhler; Rami El Shafie; Fabian Weykamp; Laila König; Nathalie Arians; Sebastian Adeberg; Laura Michel; Katharina Smetanay; Michael Golatta; Christof Sohn; Jörg Heil; Andreas Schneeweiss; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.